Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Dec;38(12):2695–2701. doi: 10.1128/aac.38.12.2695

Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.

P Le Conte 1, F Le Gallou 1, G Potel 1, L Struillou 1, D Baron 1, H B Drugeon 1
PMCID: PMC188272  PMID: 7535036

Abstract

Capreomycin was incorporated into multilamellar vesicles of pure dipalmitoylphosphatidylcholine. The pharmacokinetics and nephrotoxicity of capreomycin in the free and liposomal forms were studied in normal mice. The efficacies of the two forms were evaluated by using the Mycobacterium avium complex beige mouse model. Approximately 10(7) viable M. avium cells were injected intravenously. Seven days later, treatment with either liposomal or free capreomycin at 60 or 120 mg/kg of body weight was administered daily for 5 days. Mice were sacrificed 5 days after the end of treatment, and the viable bacteria in liver, spleen, lungs, and blood were counted. After 5 days of treatment with dosages of 60 or 120 mg/kg/day, the level of blood urea nitrogen increased in the group treated with free capreomycin but not in the group treated with liposomal capreomycin. After intravenous injection of 120 mg/kg, liposomes enhanced the diffusion of capreomycin in the spleen, lungs, and kidneys and increased the half-life in serum. The 120-mg/kg dose of liposomal capreomycin significantly reduced the number of viable mycobacteria in the liver, spleen, and blood compared with those in the controls. Although these results are promising, further studies are needed to assess the efficacy of liposomal capreomycin for the treatment of M. avium complex infections.

Full text

PDF
2695

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker-Woudenberg I. A., Lokerse A. F., ten Kate M. T., Melissen P. M., van Vianen W., van Etten E. W. Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections. Eur J Clin Microbiol Infect Dis. 1993;12 (Suppl 1):S61–S67. doi: 10.1007/BF02389881. [DOI] [PubMed] [Google Scholar]
  2. Bermudez L. E., Yau-Young A. O., Lin J. P., Cogger J., Young L. S. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. J Infect Dis. 1990 Jun;161(6):1262–1268. doi: 10.1093/infdis/161.6.1262. [DOI] [PubMed] [Google Scholar]
  3. Bertram M. A., Inderlied C. B., Yadegar S., Kolanoski P., Yamada J. K., Young L. S. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis. 1986 Jul;154(1):194–195. doi: 10.1093/infdis/154.1.194. [DOI] [PubMed] [Google Scholar]
  4. Black H. R., Griffith R. S., Peabody A. M. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann N Y Acad Sci. 1966 Apr 20;135(2):974–982. doi: 10.1111/j.1749-6632.1966.tb45538.x. [DOI] [PubMed] [Google Scholar]
  5. Brown S. T., Edwards F. F., Bernard E. M., Tong W., Armstrong D. Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. Antimicrob Agents Chemother. 1993 Mar;37(3):398–402. doi: 10.1128/aac.37.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Browning R. H., Donnerberg R. L. Capreomycin-experiences in patient acceptance and toxicity. Ann N Y Acad Sci. 1966 Apr 20;135(2):1057–1064. doi: 10.1111/j.1749-6632.1966.tb45546.x. [DOI] [PubMed] [Google Scholar]
  7. Burjanová B., Urbancik R. Experimental chemotherapy of mycobacterioses provoked by atypical mycobacteria. Bibl Tuberc. 1970;26:154–188. [PubMed] [Google Scholar]
  8. Cynamon M. H., Klemens S. P. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother. 1992 Aug;36(8):1611–1613. doi: 10.1128/aac.36.8.1611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cynamon M. H., Klemens S. P., Swenson C. E. TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice. J Antimicrob Chemother. 1992 Jun;29(6):693–699. doi: 10.1093/jac/29.6.693. [DOI] [PubMed] [Google Scholar]
  10. Cynamon M. H., Swenson C. E., Palmer G. S., Ginsberg R. S. Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1989 Aug;33(8):1179–1183. doi: 10.1128/aac.33.8.1179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  12. Donomae I. Capreomycin in the treatment of pulmonary tuberculosis. Ann N Y Acad Sci. 1966 Apr 20;135(2):1011–1038. doi: 10.1111/j.1749-6632.1966.tb45543.x. [DOI] [PubMed] [Google Scholar]
  13. Düzgüneş N., Ashtekar D. R., Flasher D. L., Ghori N., Debs R. J., Friend D. S., Gangadharam P. R. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J Infect Dis. 1991 Jul;164(1):143–151. doi: 10.1093/infdis/164.1.143. [DOI] [PubMed] [Google Scholar]
  14. Düzgüneş N., Perumal V. K., Kesavalu L., Goldstein J. A., Debs R. J., Gangadharam P. R. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother. 1988 Sep;32(9):1404–1411. doi: 10.1128/aac.32.9.1404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ellner J. J., Goldberger M. J., Parenti D. M. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis. 1991 Jun;163(6):1326–1335. doi: 10.1093/infdis/163.6.1326. [DOI] [PubMed] [Google Scholar]
  16. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gangadharam P. R., Ashtekar D. A., Ghori N., Goldstein J. A., Debs R. J., Düzgünes N. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother. 1991 Sep;28(3):425–435. doi: 10.1093/jac/28.3.425. [DOI] [PubMed] [Google Scholar]
  18. Gangadharam P. R., Edwards C. K., 3rd, Murthy P. S., Pratt P. F. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis. 1983 May;127(5):648–649. doi: 10.1164/arrd.1983.127.5.648. [DOI] [PubMed] [Google Scholar]
  19. Gangadharam P. R., Perumal V. K., Podapati N. R., Kesavalu L., Iseman M. D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1988 Sep;32(9):1400–1403. doi: 10.1128/aac.32.9.1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gilchrist J. E., Campbell J. E., Donnelly C. B., Peeler J. T., Delaney J. M. Spiral plate method for bacterial determination. Appl Microbiol. 1973 Feb;25(2):244–252. doi: 10.1128/am.25.2.244-252.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gruner S. M., Lenk R. P., Janoff A. S., Ostro M. J. Novel multilayered lipid vesicles: comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles. Biochemistry. 1985 Jun 4;24(12):2833–2842. doi: 10.1021/bi00333a004. [DOI] [PubMed] [Google Scholar]
  22. Hawkins C. C., Gold J. W., Whimbey E., Kiehn T. E., Brannon P., Cammarata R., Brown A. E., Armstrong D. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Aug;105(2):184–188. doi: 10.7326/0003-4819-105-2-184. [DOI] [PubMed] [Google Scholar]
  23. Heifets L. B., Iseman M. D., Lindholm-Levy P. J., Kanes W. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother. 1985 Oct;28(4):570–575. doi: 10.1128/aac.28.4.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  25. Heifets L. B., Lindholm-Levy P. J., Comstock R. D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856–858. doi: 10.1164/ajrccm/145.4_Pt_1.856. [DOI] [PubMed] [Google Scholar]
  26. Heifets L., Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother. 1989 Aug;33(8):1298–1301. doi: 10.1128/aac.33.8.1298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988 Aug;32(8):1131–1136. doi: 10.1128/aac.32.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Hesling C. M. Treatment with capreomycin, with special reference to toxic effects. Tubercle. 1969 Mar;50(Suppl):39–41. [PubMed] [Google Scholar]
  29. Hopewell P., Cynamon M., Starke J., Iseman M., O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of infections caused by the Mycobacterium avium complex. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S296–S306. doi: 10.1093/clind/15.supplement_1.s296. [DOI] [PubMed] [Google Scholar]
  30. Horsburgh C. R., Jr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 9;324(19):1332–1338. doi: 10.1056/NEJM199105093241906. [DOI] [PubMed] [Google Scholar]
  31. Inderlied C. B., Kolonoski P. T., Wu M., Young L. S. Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. Antimicrob Agents Chemother. 1989 Feb;33(2):176–180. doi: 10.1128/aac.33.2.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Inderlied C. B., Kolonoski P. T., Wu M., Young L. S. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis. 1989 May;159(5):994–997. doi: 10.1093/infdis/159.5.994. [DOI] [PubMed] [Google Scholar]
  33. Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother. 1987 Nov;31(11):1697–1702. doi: 10.1128/aac.31.11.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Klemens S. P., Cynamon M. H., Swenson C. E., Ginsberg R. S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1990 Jun;34(6):967–970. doi: 10.1128/aac.34.6.967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Klemens S. P., DeStefano M. S., Cynamon M. H. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2413–2417. doi: 10.1128/aac.36.11.2413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lazard T., Perronne C., Cohen Y., Grosset J., Vilde J. L., Pocidalo J. J. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother. 1993 Apr;37(4):692–695. doi: 10.1128/aac.37.4.692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lee C. N., Heifets L. B. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am Rev Respir Dis. 1987 Aug;136(2):349–352. doi: 10.1164/ajrccm/136.2.349. [DOI] [PubMed] [Google Scholar]
  38. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother. 1987 May;31(5):675–678. doi: 10.1128/aac.31.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Middlebrook G., Reggiardo Z., Tigertt W. D. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis. 1977 Jun;115(6):1066–1069. doi: 10.1164/arrd.1977.115.6.1066. [DOI] [PubMed] [Google Scholar]
  40. Morgan J. R., Williams K. E. Preparation and properties of liposome-associated gentamicin. Antimicrob Agents Chemother. 1980 Apr;17(4):544–548. doi: 10.1128/aac.17.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Musial C. E., Tice L. S., Stockman L., Roberts G. D. Identification of mycobacteria from culture by using the Gen-Probe Rapid Diagnostic System for Mycobacterium avium complex and Mycobacterium tuberculosis complex. J Clin Microbiol. 1988 Oct;26(10):2120–2123. doi: 10.1128/jcm.26.10.2120-2123.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Nix D. E., Goodwin S. D., Peloquin C. A., Rotella D. L., Schentag J. J. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother. 1991 Oct;35(10):1947–1952. doi: 10.1128/aac.35.10.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Pocidalo J. J., Vilde J. L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother. 1990 Aug;34(8):1508–1511. doi: 10.1128/aac.34.8.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Siddiqi S. H., Libonati J. P., Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 1981 May;13(5):908–912. doi: 10.1128/jcm.13.5.908-912.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Swenson C. E., Stewart K. A., Hammett J. L., Fitzsimmons W. E., Ginsberg R. S. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother. 1990 Feb;34(2):235–240. doi: 10.1128/aac.34.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yajko D. M., Nassos P. S., Hadley W. K. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1987 Oct;31(10):1579–1584. doi: 10.1128/aac.31.10.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES